NFA
CADX

Nationwide Fund Advisors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Nationwide Fund Advisors’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-108,351
Closed -$981K – 3307
2013
Q4 		$981K Sell
108,351
-1,400
-1% -$10.1K ﹤0.01% 1883
2013
Q3 		$693K Buy
109,751
+2,745
+3% +$17.4K ﹤0.01% 2051
2013
Q2 		$730K Buy
+107,006
New +$745K ﹤0.01% 1831

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nationwide Fund Advisors's CADX Position: Q1 2014 in Review

Nationwide Fund Advisors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 108,351 shares — an estimated $981K sold.

Nationwide Fund Advisors first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $981K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Nationwide Fund Advisors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Nationwide Fund Advisors sold 108,351 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $981K.
  • Nationwide Fund Advisors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Nationwide Fund Advisors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $981K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Nationwide Fund Advisors's 13F filing for Q1 2014, filed 9 May 2014.